Steven Cohen Adverum Biotechnologies, Inc. Transaction History

Point72 Asset Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $2.04 Million - $4.76 Million	-400,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.03 - $6.02 $751,621 - $1.49 Million	248,060 Added 163.26%	400,000 $2.1 Million
Q4 2018 Feb 14, 2019	BUY	$2.87 - $5.92 $436,067 - $899,484	151,940 New	151,940 $479,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $611M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.